Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- Vanda Vaults From Dog House to Drug Approval
- If there was one biotech on every banker's list of cash shells, one dog that could make bankruptcy look like a good option, one name synonymous with snickers and snide comments, it was Vanda Pharmaceuticals. Which makes the FDA's approval of Vanda's schizophrenia drug Fanapt iloperidone surprising, to say the least. ...
- Blog posts 2009-05-08
Additional Resources
- Vanda/Novartis: ... And the Circle of Life is Complete
- The surprise approval of iloperidone Fanapt earned back in May by Vanda Pharmaceuticals had a lot of people (OK maybe just us?) scratching their heads to come up with comparable instances of molecules that were dumped by pharma and eventually made it to market. Like our lion king friends here,...
- News items 2009-10-13
- Vanda Pharma Surges on FDA Approval
- ValueHuntr submits: Shares of Vanda Pharmaceuticals Inc. VNDA skyrocketed today after the company said the FDA approved its schizophrenia drug Fanapt. Vanda plans to begin shipping the drug to pharmacies later this year. The news sent Vanda shares surging nearly tenfold to $10.00 from $1.08. We purchased the stock at...
- External links 2009-05-07
- Titan Pharmaceuticals' Story Is Just Beginning
- VFC submits: Titan Pharmaceuticals (TTNP.PK) rose another 25%, and may still rise further, after the recent FDA approval of Fanapt. Fanapt, produced by Vanda Pharmaceuticals VNDA to treat schizophrenia, is Titan's licensed product from which it will receive royalty payments of between 8%-10% from net sales of the product....
- External links 2009-05-27
- Titan Pharma Investors' Wait Will Be Well Worth It
- VFC submits: Shares of Titan Pharmaceuticals (TTNP.PK) continue to trade in a somewhat flat trading range as investors eagerly await the anticipated fourth quarter launch of Fanapt - a schizophrenia drug produced by Vanda Pharmaceuticals VNDA - of which Titan will receive between 8-10% in royalties. It's been long...
- External links 2009-09-30
- Vanda reaps $200M upfront in Novartis drug pact
- Shares of Vanda Pharmaceuticals swiftly shot up this morning after the developer announced a new licensing deal with Novartis that will be worth up to $265 million--with a whopping $200 million of that coming in an upfront payment. Novartis is paying for the exclusive rights to market Vanda's...
- News items 2009-10-13
- Vanda Holding Up Well
- VNDA: UPGRADED To $22 As equities reversed hard on Wednesday afternoon, one of the few stocks that held up well on my screen was biotech Vanda Pharmaceuticals VNDA. VNDA has been consolidating for the past two weeks between $10-12.5 after having run up 1000% after...
- External links 2009-05-22
- Vanda Pharmaceuticals Comes Back from the Dead
- Derek Lowe submits: I wrote last summer about Vanda Pharmaceuticals VNDA and their difficulty getting a new antipsychotic Fanapt iloperidone through the FDA. At the time, they'd received one of those wonderful requests for more information from the agency, of the kind that spread cheer whenever they appear. I...
- External links 2009-07-01
- Vanda Pharmaceuticals: Heavily Undervalued
- Vanda Pharmaceuticals VNDA is making a stunning come back this year as FDA finally approved its schizophrenia drug Fanapt. But the story is far from over, and there is every reason to believe VNDA is still heavily undervalued and has huge upside potential. This is a potential giant market for...
- External links 2009-07-08
- The Worst Is Way Behind Titan Pharma
- VFC submits: [Update below] I've discussed Titan Pharmaceuticals (TTNP.PK) in great depth here over the past eight months or so, but a rundown of where I think this stock could go - based on the potential of Fanapt sales and Titan's 8-10% royalty rate - is as follows: by...
- External links 2009-10-02
- Vanda Headed Higher on Novartis Deal
- VFC submits: Shares of Vanda Pharmaceuticals VNDA are set to trade to the upside on Tuesday after news was released on Monday evening detailing a licensing agreement with Novartis NVS for Fanapt that could be worth as much as $465 million. VNDA traded higher by 20% during the after...
- External links 2009-10-13
- Titan Pharmaceuticals Still a Buy
- VFC submits: TTNP.PK: Shares of Titan Pharmaceuticals traded to the upside on Tuesday after Vanda's VNDA Fanapt licensing agreement with Novartis NVS was announced on Monday.Titan actually performed somewhat better than I expected and I still consider the stock a buy for below two dollars - for the short...
- External links 2009-10-14
- Titan Pharma Stock Remains Primed to Spike
- VFC submits: Titan Pharmaceuticals (TTNP.PK) was mentioned in a weekend article by the Washington Post that highlighted the CEO of Vanda Pharmaceuticals, Mihael Polymeropoulos, and Fanapt - Vanda's recently approved drug to treat schizophrenia of which Titan will reap up to 10% in royalties.While Novartis NVS emerged as Vanda's...
- External links 2009-11-03
- Titan Pharmaceuticals: The Future Looks Bright
- VFC submits: Shares of Titan Pharmaceuticals (TTNP.PK) dropped to the $1.81 level during early trading on Tuesday in what could be considered an attempt to 'shake' a few more shares loose - considering the fact that volume was nearing a stand still at the $1.90 level. With Fanapt royalties...
- External links 2009-11-10
- Titan Pharmaceuticals: Finally Reaching Its Potential
- VFC submits: It was a quick rise to the $2.40 level for shares of Titan Pharmaceuticals (TTNP.PK), as it finally looks like the stock is starting to trade towards its potential. With the heavyweight Novartis NVS set to commercially launch Fanapt early next year, the schizophrenia drug could quickly...
- External links 2009-11-17
- << Previous
- page 1 of 1
- Next >>
